Agenus shared a post on LinkedIn:
“During his ESMO-IO 2025 spotlight lecture, Dr. Steven O’Day highlighted how CTLA-4 has re-emerged as a central driver of the next immuno-oncology revolution. Drawing from historical context and new mechanistic insights, he outlined:
- The limitations of first-generation CTLA-4 agents
- How Fc-enhanced designs improve T-cell priming, Treg depletion & myeloid activation
- Why CTLA-4 is essential to IO Revolution 2.0
Read the full presentation.”
More posts about ESMO Immuno 2025.